Empowered Patient Podcast

Dr. Jean-Marc Steens, Chief Medical Officer, Abivax reports on clinical results that continue to show advances in the chronic treatment and maintenance of moderate to severe ulcerative colitis using a new small molecule ABX464 in an oral treatment and potential applications for other inflammatory and neurological diseases.

Jean-Marc also explains how another molecule ABX196 is being tested to determine if it might increase the outcome of treatments for hepatocellular carcinoma, the most common liver cancer, in conjunction with Opdivo a checkpoint inhibitor that is being developed with Scripps Research, University of Chicago and BYU.

Read the transcript and listen to the podcast.

Dr. Jean-Marc Steens, Chief Medical Officer, Abivax reports on clinical results that continue to show advances in the chronic treatment and maintenance of moderate to severe ulcerative colitis using a new small molecule ABX464 in an oral treatment and potential applications for other inflammatory and neurological diseases.

Jean-Marc also explains how another molecule ABX196 is being tested to determine if it might increase the outcome of treatments for hepatocellular carcinoma, the most common liver cancer, in conjunction with Opdivo a checkpoint inhibitor that is being developed with Scripps Research, University of Chicago and BYU.

#ulcerativecolitis

Abivax

Bob Anderson PhD, Chief Scientific Officer, ImmusanT is an internationally recognized leader in celiac disease research. He talks about the underlying causes of celiac, who is most likely to have an acquired immune response to fragments of the gluten protein, educating doctors about the need to test for celiac, the Phase 2 clinical trial results for Nexvax2 a therapeutic vaccine to treat celiac, and how the ImmusanT platform technology is allowing development of therapeutic vaccines for diabetes and other autoimmune conditions.

@ImmusanT

#celiac #celiacdisease #diabetes #autoimmunediseases #tcell #glutenpeptides #peptides #gluten #immunology

ImmusanT

Amit Etkin MD PhD is a professor of psychiatry and behavioral sciences at the Stanford School of Medicine and expert in the neural basis of emotional disorders. He talks about a recent study published in Science Translational Medicine, of which he was the lead author physician, on his research that lead to the discovery of the first imaging biomaker for PTSD. Using fMRI and TMS with EEG, Amit was able to identify which patients were most likely to be helped by different treatment plans for post-traumatic stress disorder.

This research was funded in part by Cohen Veterans Bioscience, a translational research organization dedicated to fast-tracking personalized diagnostics and therapeutics for brain health.

Cohen Veterans Bioscience

Dr. Vimal Mehta, CEO and Founder, BioXcel Therapeutics talks about using artificial intelligence approaches in the development of drugs. BioXcel's two most advanced clinical development programs are (1) BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders like schizophrenia, bipolar disorder, Alzheimer's and opioid addiction and (2) BXCL701, an immuno-oncology agent designed for the treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

BioXCel Therapeutics

Marina Baroff, Senior Director, Service Innovation at Steps Through OC shines a light on the need to provide physical as well as emotional support to women living with ovarian cancer and their caregivers. Marina talks about this new program of The Clearity Foundation with seed funding provided by the Susan Poorman Blackie Ovarian Cancer Foundation that matches patients and their caregivers with a professional ovarian cancer counselor at no charge. This is not a support group but rather online, personalized treatment plans based on science and tailored to each person's unique situation.

@stepsthrough

@clearityfnd

StepsThrough.org

ClearityFoundation.org

Dr. Jay Venkatesan, CEO, Angion, a clinical stage biopharmaceutical company, discusses the company's work in organ self-repair and their initial focus in the nephrology space. The company's lead candidate ANG-3777 is a small molecule that mimics a protein to stimulate this self-repair and regeneration following injury. Angion's therapeutic programs modulate the natural repair pathways of the body to fill unmet medical needs across many indications, including acute kidney injury, kidney transplantation, and chronic kidney disease.

#organinjury #organtransplant #acutekidneyinjury #chronickidneydisease

Angion

William Annett, CEO, OncoCyte discusses the exciting work the company is doing in the liquid biopsy space. They have developed DetermaVu™ a liquid biopsy test for lung cancer, which studies show has the potential to detect the absence of cancer by analyzing a simple blood sample. This technique allows individuals to potentially avoid risky, expensive lung biopsies. The company recently announced promising R&D validation data and is planning to make the test available to patients and physicians later this year.

@OncocyteLbx

#LiquidBiopsy #LungCancer #DetermaVu

OncoCyte.com

Dr. Hartmut Ehrlich, CEO of Abivax discusses the exciting new progress that this French biotechnology company has observed in clinical trials of their most advanced clinical drug candidate, ABX464. Originally designed to treat HIV by reducing the viral reservoir, Abivax determined the molecule could also be a game-changing treatment in a variety of inflammatory conditions like ulcerative colitis, Crohn's disease and arthritis.

#Abivax #ABVX #HIV #UlcerativeColitis #UC #inflammation #IBD

Abivax.com

Anna Landre is a Georgetown University sophomore who has a rare disease, spinal muscular atrophy (SMA) and is a wheelchair user. In addition to being a full time student, Anna serves as Commissioner of the Advisory Neighborhood Commission where she advocates for people with disabilities and to improve accessibility on the Georgetown campus and in the district. She talks about educating elected officials about possible ways to overcome challenges for those in wheelchairs and raising awareness about those living with rare diseases.

#onestepaway #SMA #cureSMA